Values as of: 2024-07-16
COMMON STOCK | Biotechnology |
Last Closing
USD 1.68Change
+0.02 (+1.20)%Market Cap
USD 0.10BVolume
0.11MAnalyst Target
USD 9.28Verdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc |
-2.47 (-0.21%) |
USD 132.22B |
| VRTX | Vertex Pharmaceuticals Inc |
+9.43 (+1.96%) |
USD 124.57B |
| ALNY | Alnylam Pharmaceuticals Inc |
+0.44 (+0.16%) |
USD 35.98B |
| MRNA | Moderna Inc |
-0.62 (-0.79%) |
USD 31.68B |
| ARGX | argenx NV ADR |
+2.35 (+0.45%) |
USD 31.25B |
| BGNE | BeiGene Ltd |
-4.01 (-1.98%) |
USD 22.05B |
| BMRN | Biomarin Pharmaceutical Inc |
-0.14 (-0.15%) |
USD 17.14B |
| RPRX | Royalty Pharma Plc |
+0.29 (+1.02%) |
USD 16.73B |
| UTHR | United Therapeutics Corporatio.. |
+10.61 (+3.04%) |
USD 15.42B |
| INSM | Insmed Inc |
-0.58 (-0.75%) |
USD 13.55B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| ZEO:CA | BMO Equal Weight Oil & Ga.. | 9.00 % | 0.61 % |
-0.36 (-0.27%) |
CAD 0.22B |
| XEG:CA | iShares S&P/TSX Capped En.. | 4.77 % | 0.61 % |
-0.08 (-0.27%) |
CAD 1.61B |
| XMD:CA | iShares S&P/TSX Completio.. | 2.21 % | 0.61 % |
-0.35 (-0.27%) |
CAD 0.21B |
| VSS | Vanguard FTSE All-World e.. | 0.32 % | 0.12 % |
-0.95 (-0.27%) |
USD 8.85B |
| ENY | 0.00 % | 0.66 % |
N/A |
N/A | |
| FQC:CA | 0.00 % | 1.01 % |
N/A |
N/A | |
| HEE:CA | 0.00 % | 0.84 % |
N/A |
N/A | |
| SCHC | Schwab International Smal.. | 0.00 % | 0.12 % |
-0.35 (-0.27%) |
N/A |
| ZJO:CA | 0.00 % | 0.60 % |
N/A |
N/A | |
| BREA:CA | Brompton Sustainable Real.. | 0.00 % | 0.00 % |
-0.07 (-0.27%) |
CAD 0.02B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.07% | 57% | F | 54% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 3.07% | 57% | F | 52% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -58.31% | 28% | F | 17% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -58.31% | 28% | F | 16% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -46.50% | 55% | F | 27% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -46.50% | 55% | F | 25% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.07% | 62% | D | 56% | F | ||
| Dividend Return | 3.07% | 62% | D | 52% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 74.72% | 37% | F | 21% | F | ||
| Risk Adjusted Return | 4.11% | 61% | D- | 43% | F | ||
| Market Capitalization | 0.10B | 45% | F | 38% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total free cash flow in the most recent four quarters.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total earnings in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
